HomeSWOBY • OTCMKTS
add
Swedish Orphan Biovitrum ADR
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 7.44B | 8.65% |
Operating expense | 4.17B | 15.32% |
Net income | 1.40B | 36.16% |
Net profit margin | 18.79 | 25.35% |
Earnings per share | 3.98 | 25.16% |
EBITDA | 2.34B | -6.42% |
Effective tax rate | 3.27% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.14B | 26.11% |
Total assets | 75.44B | 1.91% |
Total liabilities | 35.15B | -12.48% |
Total equity | 40.30B | — |
Shares outstanding | 343.44M | — |
Price to book | 0.12 | — |
Return on assets | 5.53% | — |
Return on capital | 7.29% | — |
Cash Flow
Net change in cash
| (SEK) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 1.40B | 36.16% |
Cash from operations | 1.80B | 67.63% |
Cash from investing | -101.00M | 77.95% |
Cash from financing | -1.15B | -221.23% |
Net change in cash | 546.00M | 141.59% |
Free cash flow | 2.90B | 375.08% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,806
